A retrospective medical chart review of clinical outcomes in children and adolescents with attention-deficit/hyperactivity disorder treated with guanfacine extended-release in routine Canadian clinical practice

Judy van Stralen1*, Simerpal K. Gill2, Christopher J. Reaume3 and Kenneth Handelman4

Abstract
Objective: This study evaluated clinical outcomes in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) treated with the α2-adrenoceptor agonist guanfacine extended-release (GXR) in routine Canadian clinical practice.

Methods: This retrospective chart review focused on patients with ADHD aged 6–17 years initiating treatment with GXR as monotherapy or adjunctive therapy. Patients were followed for up to 12 months after GXR initiation and, if they had received prior ADHD pharmacotherapy, for 12 months before GXR initiation. The primary outcome was change in ADHD symptoms and functionality based on physician assessments, classified as improvement, no change, or worsening relative to the time of GXR initiation. Treatment-emergent adverse events (TEAEs) were evaluated. Clinical outcomes were also analyzed post hoc according to whether GXR treatment was received as monotherapy or adjunctive therapy, and by select psychiatric comorbidities. Exploratory analyses were conducted in patients who had received prior ADHD pharmacotherapy to evaluate clinical outcomes after initiating GXR.

Results: Improvements in ADHD symptoms were reported for 232/330 (70.3%) patients. Functional improvements in school performance and home life were reported for 213/330 (64.5%) and 209/330 (63.3%) patients, respectively. The most frequent TEAEs (≥5%) were somnolence, headache, insomnia, presyncope, and decreased appetite. Improvements in ADHD symptoms were observed when GXR was received as either monotherapy (35/60 [58.3%]) or adjunctive therapy (197/270 [73.0%]). Improvements in ADHD symptoms and functionality were observed in the majority of patients with select psychiatric comorbidities. Among patients who had experienced worsening of symptoms with prior ADHD pharmacotherapy, 44/54 (81.5%) experienced symptom improvement, 33/44 (75.0%) who had previously experienced worsening of school performance improved, and 34/48 (70.8%) who had previously experienced worsening of home life improved.

Conclusion: In Canadian routine clinical practice, most children and adolescents with ADHD treated with GXR experienced improvements in ADHD symptoms and in functionality both at school and at home.

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder with childhood onset characterized by a pervasive pattern of age-inappropriate and excessive inattention and hyperactivity/impulsivity [1]. The estimated worldwide prevalence of ADHD is ~ 5.3% [2]. From 2003 to 2011 ADHD incidence grew an average of 5% yearly, due to increased recognition and diagnosis [3]. Canadian ADHD prevalence rates are consistent with worldwide estimates; a recent retrospective review of medical records from Ontario found a prevalence rate of 5.4% (males, 7.9%; females, 2.7%) [4].

The socioeconomic burden of ADHD is considerable, impairing many aspects of children’s lives and their families, and negatively affecting academic performance and interpersonal relationships. Specific manifestations may include inattention and distractibility in daily routines, impulsive behavior, or missing social cues [5]. In young people and adults, ADHD may also be associated with higher risk of self-harm, traffic accidents, delinquency, and substance misuse [6].

In the United States, healthcare costs for children and adolescents with ADHD have been estimated at $US 7.9 billion annually (2005 costs) [7]. Additionally, total costs, including excess costs associated with healthcare and work loss among family members of people with ADHD have been estimated to be $US 34.6 billion annually (2000 costs) [8]. In Canada, total ADHD-associated costs are estimated to exceed $CA 7 billion [9].

Both psychosocial and pharmacologic interventions are used for ADHD treatment. Combination therapy with approved medication and behavioral therapy is the preferred model for children aged ≥ 6 years and adolescents [10]. Stimulants such as methylphenidate and amphetamines are the mainstay of ADHD therapy. However, a single stimulant may not adequately control ADHD symptoms in 25–30% of children [11, 12]. Impairments associated with residual ADHD symptoms in patients suboptimally treated with stimulants, and the need to optimize therapy, are becoming increasingly recognized [13]. Furthermore, some patients may not tolerate stimulants. In Canada, non-stimulant alternatives such as atomoxetine and guanfacine extended-release (GXR) are available as monotherapy for patients who do not respond to or cannot tolerate first-line stimulant therapy [14]. As a selective α2-adrenoceptor agonist, GXR can also be used as adjunctive therapy to stimulants [14, 15].

Real-world evidence provides valuable knowledge beyond the ideal conditions of a clinical trial, and several such studies have assessed usage patterns and costs of non-stimulants in patients with ADHD [16, 17]. However, GXR utilization in routine clinical care is less clear. Real-world experience with GXR has accumulated in Canada, where it has been available to treat ADHD since 2013 as an extended-release tablet and is approved for patients aged 6–17 years for the treatment of ADHD either as monotherapy or adjunctive therapy to stimulants if response to stimulants is suboptimal [15]. In randomized controlled clinical trials, GXR has been effective and well tolerated as monotherapy and adjunctive therapy [18–25]. Additionally, GXR lacks potential for abuse and may be used with stimulant medications [26]. The purpose of this study was to evaluate clinical outcomes in children and adolescents with ADHD treated with the α2-adrenoceptor agonist GXR in routine Canadian clinical practice.

Methods

Study design and population

This study was a retrospective medical chart review in children and adolescents with ADHD recruited from 10 sites by Canadian community- or hospital-based pediatricians, child psychiatrists, or family doctors specializing in ADHD. Included children (6–12 years) and adolescents (13–17 years) had diagnosed ADHD, had initiated treatment with GXR (monotherapy or adjunctive therapy), and had ≥ 6 months of medical chart data post-initiation of GXR (with ≥ 1 follow-up; if applicable, this included the visit when GXR was discontinued). Patients could have been treatment naive or received other pharmacotherapy before GXR initiation. In treatment-naive patients, the observation period of the chart review began at treatment initiation, whereas in patients who had received prior ADHD pharmacotherapy, the observation period started 12 months prior to GXR initiation. The chart review observation period ended at ≤ 12 months after GXR initiation. If GXR was discontinued, the reason for discontinuation was noted but no other follow-up data were extracted after the discontinuation visit.

Data collection and outcome measures extracted

Data were transcribed from patient charts to case report forms (CRFs) by the site investigator or designated staff and sent to a central database. No patient identifying information was recorded; patients were given encrypted random study identification numbers. Data on patient demographics and clinical
characteristics were extracted from patient charts per standard of care for ADHD. At ADHD diagnosis, these data included diagnosis date, sociodemographics (age, gender, ethnicity, location of residence [urban vs rural]), medical history, and comorbidities. At GXR initiation, data extracted included reason for GXR initiation, prior non-pharmacologic treatments for ADHD or comorbid conditions, and prior pharmacologic treatments, including stimulants, non-stimulants, and atypical antipsychotics (AAPs) for ADHD or comorbid psychiatric conditions/symptoms. At GXR initiation and for its duration, covariates included GXR information (dose, frequency, dose/frequency changes and reasons, termination date and reason) and pharmacologic treatment for ADHD or comorbid psychiatric symptoms. If GXR was discontinued, reasons for discontinuation and any subsequent ADHD-related pharmacologic treatment regimen were recorded, and no additional follow-up details were extracted following the discontinuation visit.

Extracted outcome data were from the time prior to (for patients receiving prior pharmacologic treatment only), at GXR initiation, and for its duration (≤12 months). ADHD symptoms and functionality were measured using the General Physician Symptom Assessment and General Physician Functional Assessment (school grades/performance and homelife), respectively. Rating scale data on ADHD symptoms and functionality, if available in patient charts, were also extracted and evaluated. Symptom ratings scales included Swanson, Nolan, and Pelham-IV (SNAP-IV-26) [27], National Institute for Children's Health Quality (NICHQ) Vanderbilt Assessment Scale and Follow-up-Parent Information [28], and Conners 3-Parents (Conners 3-P) [29]. The Weiss Functional Impairment Rating Scale-Parent Report (WFIRS-P) was used to measure functionality [30]. To minimize recall bias related to subjective assessment of symptomatology (as extracted from patients’ charts in the absence of validated scales), outcome recorders were requested to categorize consistently the patient’s response, as indicated in the patient charts. Outcome recorders had prior training including how to record consistently a category for patient responses based on data in patient charts. ADHD symptoms and functionality were categorized as “improvement”, “no change”, or “worsening” based on rating scales in medical charts, and/or clinician’s notes. An improvement/worsening of symptoms or functionality for two consecutive visits was categorized as “improved” or “worsening”, respectively.

Treatment-emergent adverse events (TEAEs) occurring during GXR treatment were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 20 and described by the proportion of patients experiencing a TEAE within each Preferred Term and System Organ Class.

Sample size
Charts from a minimum of 252 and maximum of 444 patients were required. In research by Cutler et al. [31], symptomatic remission was achieved in 62.2% versus 46.1% of patients with ADHD aged 6–17 years with suboptimal response to stimulants treated with GXR plus stimulant versus placebo plus stimulant, respectively. Based on these data, the assumption was that ~60% of patients in this study would experience symptom improvement. To detect a significant difference in response with α = 5% and 80% power, 202 evaluable patients were required. Allowing that required data would not be available in 25% of charts, data from a minimum of 252 charts were required.

In Cutler et al. [31], 77.3% of patients experienced a TEAE. Assuming a similar rate in our study with 252 patients, the precision of estimate as assessed with the width of the 95% confidence interval (CI) would be 13.5% of the estimate (0.104), which is within acceptable limits. To achieve 10% precision (0.078), 444 patients would be required. With 252 and 444 patients, the probability of detecting a TEAE with true incidence of 1% was 92% and 99%, respectively.

Statistical methods
Summary statistics were calculated for all study variables, including mean, median, standard deviation (SD), 95% CI of the mean, and frequency distributions for continuous scale variables.

The primary analysis was change in ADHD symptoms and functionality, assessed by the proportion of patients showing improvement versus no change versus worsening. For patients without previous ADHD treatment, this categorization was based on assessment of the patient compared with the previous visit (beginning with the comparison of the first assessment post-GXR initiation to status at initiation). For patients who had received prior ADHD pharmacologic treatment, the pre-GXR value corresponded to the overall response (improved, no change, or worse) to the last treatment regimen administered prior to GXR initiation. An improvement/worsening of symptoms or function was defined as a categorization of patient response as improved or worse, respectively, for two consecutive visits. The best symptom and functionality responses were described, corresponding to the best respective responses registered during the post-GXR initiation observation period while receiving GXR.

Post-hoc analyses (unspecified in the protocol) included assessments of symptoms and functionality whether GXR treatment was monotherapy/adjunctive
therapy, if patients had been initiated on GXR to reduce use of AAPs, and according to psychiatric comorbidities of interest (oppositional defiant disorder, learning disability, anxiety, and autism spectrum disorder).

Data from patients who had received ADHD pharmacologic treatment before GXR and had ≤12 months of data following GXR initiation, a subset not considered in power calculations, were examined in exploratory analyses. The objective was to assess the impact on clinical outcomes of switching to GXR or adding GXR to current ADHD treatment. The pre-GXR value (prior period) corresponded to the overall response (improved, no change, or worse) to the last treatment regimen administered before GXR initiation. The analyses detailed for the primary objective were repeated in this subgroup, although the post-hoc breakdown of results (by monotherapy/adjunctive therapy, etc.) was not conducted. The comparison of the response rate (improvement vs no change vs worsening) of General Physician Symptom and Functional Assessments before and after GXR initiation was conducted with the extension of McNemar’s test (Bowker’s test); two-tailed test. The null hypothesis was that the percentages are equal before and after GXR initiation, i.e., during the baseline period and post-GXR initiation observation period (exploratory analysis).

As this was a retrospective chart review, no missing data could be retrieved. However, cross-validation was performed, and erroneous data were clarified with physicians. Partial dates were completed using the most conservative approach when required to determine duration of observation, treatment exposure, and incidence of adverse events. Otherwise, all analyses were conducted on available data with no data imputation.

**Results**

Study sites were activated on a rolling basis beginning on 5 October 2016; database lock occurred on 16 June 2017.

**Patient characteristics**

In total, 330 charts were screened, and all patients were included in the analysis (Additional file 1: Table S1). Approximately 92% and 40% had prior pharmacologic and non-pharmacologic ADHD treatment within the 12 months preceding GXR initiation, respectively. The majority of patients were male Caucasian children (6–12 years) living in Ontario.

Comorbid psychiatric conditions were reported for 215/330 (65.2%) patients. The most frequently reported conditions experienced by ≥5% of patients were oppositional defiant disorder (n = 92, 27.9%), learning disability (n = 70, 21.2%), anxiety (n = 53, 16.1%), autism spectrum disorder (n = 35, 10.6%), and tic (n = 18, 5.5%).

A total of 270 (81.8%) patients concomitantly used other pharmacological treatments for ADHD and comorbid psychiatric conditions while on GXR. The most frequently used medications included methylphenidate (n = 123, 37.3%), lisdexamfetamine (n = 121, 36.7%), methylphenidate (n = 126, 7.9%), centrally acting sympathomimetics (n = 24, 7.3%), apiprazole (n = 25, 7.6%), and risperidone (n = 18, 5.5%). Six (1.8%) patients used clonidine, 1 (0.3%) patient used trazodone, and 40 patients used SSRIs (citalopram, n = 3, 0.9%; escitalopram, n = 13, 13.9%; fluoxetine, n = 16, 4.8%; paroxetine, n = 1, 0.3%; sertraline, n = 7, 2.1%).

**Characteristics of GXR treatment in the study**

The most common reasons for GXR initiation were non-optimal control of ADHD symptoms, to improve response to stimulants, to extend duration of effect of stimulants, and to avoid increasing doses of ADHD stimulants (Additional file 1: Table S2). Compared with 60 (18.2%) patients receiving monotherapy, 270 (81.8%) received GXR adjunctive therapy. The median daily dose of GXR at initiation was 1.0 mg. Of the 325/330 (98.5%) patients who changed GXR dose during post-GXR initiation observation, 307/325 (94.5%) had an increase and 18/325 (5.5%) had a decrease. The mean (SD) total dose change for all patients was 2.4 mg (0.5 mg). The mean (SD) length of GXR treatment was 7.9 (3.6) months and was similar between children (n = 242) and adolescents (n = 88). After a median (range) of 8.4 (0.2–12) months, almost 80% of patients were continuing GXR treatment (~20% discontinued). The most common reasons for discontinuation were safety/tolerability issues.

**Primary analysis: assessments of symptoms and functionality while receiving GXR**

Improvements in clinical outcomes were reported for >70% of patients receiving GXR (Fig. 1). No change/worsening of ADHD symptoms was observed for <5% of patients receiving GXR (missing data, 77 [23.3%]). Additionally, >60% of patients showed improvements in school performance and homelife while no change/worsening in school performance and homelife functionality was reported for <10% of patients.

**Safety and tolerability**

Overall, 349 TEAEs were experienced by 147/330 (44.5%) patients (Table 1). The majority were non-serious (341/349, 97.7%), mild in severity (n = 314, 90.0%), and related to GXR treatment (n = 263, 75.4%). No action was deemed necessary regarding management of GXR treatment for 53% of TEAEs. The most common TEAEs (reported in ≥5% of patients) were somnolence (n = 59/330, 17.9%), headache (n = 34/330, 10.3%),
insomnia (n = 26/330, 7.9%), presyncope (n = 22/330, 6.7%), and decreased appetite (n = 18/330, 5.5%). Eight serious TEAEs were experienced by 7 patients (Table 1). Of these, 6/8 events were moderate in severity, 7/8 were related to GXR treatment, and 7/8 were reported as resolved. A total of 4 serious TEAEs experienced by 3 patients led to GXR discontinuation, 1 serious TEAE resulted in dose interruption, and 1 serious TEAE resulted in dose reduction. No action was deemed necessary regarding GXR management for 2 serious TEAEs experienced by 2 patients.

**Post-hoc analyses: assessments of symptoms and functionality in patient subgroups**

Improvements in ADHD symptoms were observed in 35/60 (58.3%) patients receiving monotherapy and 197/270 (73.0%) patients receiving GXR adjunctive therapy. Similar improvements were seen in functionality assessments of school performance (monotherapy, 30/60 [50.0%]; adjunctive therapy, 183/270 [67.8%]) and homelife (monotherapy, 30/60 [50.0%]; adjunctive therapy, 179/270 [66.3%]).

Of the 44 patients initiated on GXR to reduce use of AAPs, ADHD symptom improvements were experienced by > 70%, including > 55% of patients in school performance and homelife functionality (Fig. 2). AAPs used included risperidone, quetiapine, and aripiprazole.
Patients with comorbid autism spectrum disorder, oppositional defiant disorder, anxiety, or learning disability experienced improvements in ADHD symptoms and functionality consistent with the primary findings (Table 2).

**Exploratory analyses: assessments in symptoms and functionality in patients who had received prior ADHD pharmacotherapy**

In the subgroup who had received prior pharmacotherapy, a greater proportion of patients who had reported worsening ADHD symptoms on prior pharmacotherapy experienced improvements on GXR compared with those reporting no changes (Table 3). Similarly, a greater proportion of patients reporting worsening changes in homelife functionality and school performance on prior pharmacotherapy experienced improvements on GXR compared with those reporting no changes.

**Discussion**

This retrospective chart review deepens our understanding of GXR use beyond the clinical trial setting, suggesting that children and adolescents with ADHD receiving GXR in real-world clinical practice experienced improvements in ADHD symptoms and functionality. These improvements were evident for the overall population (primary analysis) and patients who had experienced worsening symptoms or functionality with ADHD pharmacotherapy immediately before GXR initiation (exploratory analysis). Our data suggest that, in Canada, GXR is less commonly used as monotherapy than as adjunctive treatment. Post-hoc analyses demonstrated improvements in ADHD symptoms in 58.3% of patients using GXR as monotherapy and 73.0% of patients using GXR as adjunctive therapy, corroborating randomized, double-blind, placebo-controlled, clinical trial data demonstrating that GXR is clinically efficacious as either monotherapy or adjunctive therapy [18–25].

GXR is a selective α₂-adrenoceptor agonist. The majority of α₂-adrenoceptors are expressed at postsynaptic neurons of the prefrontal cortex, and have been shown to regulate cognitive functions [32]. Although the exact mechanism of action of GXR is unknown, it is thought that GXR stimulation of these receptors may have an effect on ADHD symptoms related to working memory, attention regulation, and response inhibition [33, 34]. This mechanism may explain its efficacy as monotherapy in patients who cannot tolerate or do not respond to stimulants and also when used with stimulants as adjunctive therapy [14, 23]. Stimulant treatment is considered

![Fig. 2](image-url)
the mainstay of ADHD therapy; however, approximately 25–30% of patients may not adequately respond to stimulants [11, 12]. Stimulants used to treat ADHD (e.g., amphetamine and methylphenidate) act via different mechanisms than GXR, inhibiting the reuptake of dopamine and norepinephrine and/or enhancing their release [33].

In this study, a relatively high proportion of patients continued treatment beyond 12 months (263/330, 79.7%). For comparison, albeit from different populations and methodologies, three large database analyses from Taiwan, Canada, and the United Kingdom found persistence criteria are applied, patients who would be typically seen in clinical practice were included, such as those with confounding comorbidities. Here, many patients were reported to have ≥1 comorbid psychiatric condition, including oppositional defiant disorder (27.9%), learning disability (21.2%), anxiety (16.1%), and autism spectrum disorder (10.6%). The results of our post-hoc analysis suggest that GXR is effective in improving ADHD symptoms and functionality in patients with ADHD with different psychiatric comorbidities or without comorbid psychiatric conditions. These findings are consistent with another study showing GXR to be effective in reducing ADHD symptoms in patients with ADHD and comorbid oppositional symptoms [21], and warrant further investigation.

The limitations of the study reported here include the inherent limitations of retrospective medical record analysis; the patients selected for study inclusion represented a convenience sample. The vast majority of patients were from Ontario and 82% of participants were Caucasian. Findings may therefore not be generalizable to or fully

| Table 3 | Categorization of clinical outcomes (ADHD symptoms and functionality)—exploratory subgroup analysis (n = 304) |
|---------|----------------------------------------------------------------------------------------------------------|
| Pre-initiation of GXR treatmenta | Post-initiation of GXR treatmentb |
| General Physician Symptom Assessment, n (%)c | Improvement | No change | Worsening |
| Improvement | 172 | 130 (75.6) | 2 (1.2) | 0 (0.0) |
| No change | 74 | 37 (50.0) | 9 (12.2) | 1 (1.4) |
| Worsening | 54 | 44 (81.5) | 2 (3.7) | 3 (5.6) |
| General Physician Functional Assessment, n (%)c | Improvement | No change | Worsening |
| Improvement | 132 | 102 (77.3) | 4 (3.0) | 1 (0.8) |
| No change | 118 | 52 (44.1) | 9 (7.6) | 2 (1.7) |
| Worsening | 48 | 34 (70.8) | 9 (18.8) | 1 (2.1) |
| School performance* | |
| Improvement | 161 | 111 (68.9) | 3 (1.9) | 0 (0.0) |
| No change | 89 | 45 (50.6) | 11 (12.4) | 2 (2.2) |
| Worsening | 44 | 33 (75.0) | 5 (11.4) | 2 (4.5) |

Exploratory subgroup analysis in a subgroup of patients who had received prior pharmacotherapy for ADHD

ADHD attention-deficit/hyperactivity disorder, GXR guanfacine extended-release

P < 0.001, derived through extension of McNemar's test (Bowker's test)

Overall response to treatment regimen administered prior to GXR administration

The best response registered while on treatment with GXR

Percentages were calculated using the corresponding categories under GXR treatment count as denominator; due to missing values, percentages in each category do not add up to 100%

rates of hypotension (1.8%) and orthostatic hypotension (0.6%) in this study were generally lower than those reported in the product monograph for patients who received GXR in clinical trials (0.7–2.5% and 1.0–3.8%, respectively). This difference may be attributed to our data originating in a real-world setting in which adverse event reporting was collected from 10 heterogeneous sites, as opposed to being prospectively reviewed in a clinical trial setting. Other potential explanations include more patients receiving GXR as adjunctive treatment to stimulants in our study (as stimulants are associated with small increases in blood pressure) [14], or that up titration was conducted slowly and at low increments. Timings of TEAEs during the course of therapy were not provided, which leaves open the possibility that some effects, such as somnolence, may have occurred at treatment initiation and then resolved.

Many physicians in Canada use AAPs in complicated or comorbid cases of ADHD [4]; however, there are concerns about metabolic side effects (requiring lab-based monitoring) associated with AAPs [38, 39], and data are lacking regarding the efficacy of AAPs in treating ADHD symptoms [4]. In this study, 44 patients were initiated on GXR by their physicians in order to lower the doses of AAPs, with post-hoc analyses showing that > 70% of these patients experienced ADHD symptom improvements. These findings may therefore be useful for informing future treatment decisions for patients with ADHD.

This was a real-world study of medical chart review data from patients with ADHD, and so included patients from a naturalistic setting. This means that, unlike in the clinical trial setting where strict exclusion/inclusion criteria are applied, patients who would be typically seen in clinical practice were included, such as those with confounding comorbidities. Here, many patients were reported to have ≥1 comorbid psychiatric condition, including oppositional defiant disorder (27.9%), learning disability (21.2%), anxiety (16.1%), and autism spectrum disorder (10.6%). The results of our post-hoc analysis suggest that GXR is effective in improving ADHD symptoms and functionality in patients with ADHD with different psychiatric comorbidities or without comorbid psychiatric conditions. These findings are consistent with another study showing GXR to be effective in reducing ADHD symptoms in patients with ADHD and comorbid oppositional symptoms [21], and warrant further investigation.

The limitations of the study reported here include the inherent limitations of retrospective medical record analysis; the patients selected for study inclusion represented a convenience sample. The vast majority of patients were from Ontario and 82% of participants were Caucasian. Findings may therefore not be generalizable to or fully
representative of the broader ADHD population in Canada. The analysis of symptom improvement during previous therapy was exploratory and limited to improvement, no change, or worsening from the overall response to the last treatment regimen. In addition, as this was a real-world study, outcomes may have been affected by factors such as adherence, access, long-term duration of therapy, and the presence of comorbidities and concomitant medications. However, compared with patients included in clinical trials, this population may represent a more accurate view of typical patients seen in routine practice.

Although data from different sites were standardized by transcription onto CRFs, it should be acknowledged that there may be inherent differences in data collection methods. Specifically, some sites used standardized methodology such as rating scales that could be used to support and analyze data further, but these data were not available for all patients or sites. Also, although the data were interpreted as accurately as possible using available clinical notes, some assumptions were made. Therefore, study findings should be interpreted in consideration of these limitations.

The maximum dose of GXR is 7 mg daily for adolescents when used as monotherapy. However, in our study, the highest dose reported was only 5 mg. This observation may relate to the fact that GXR was predominantly used as adjunctive therapy (for which the maximum recommended dose is 4 mg), or perhaps the clinicians treating these patients adopted a conservative approach to GXR dosing.

Conclusions
In routine clinical practice in Canada, most children and adolescents with ADHD treated with GXR experienced improvements in ADHD symptoms, and in functionality at both school and home. Safety data in this chart review are consistent with those reported in clinical trials. Additionally, this real-world evidence corroborates the efficacy of GXR observed in randomized controlled trials and demonstrates the effectiveness of GXR as adjunctive therapy and, albeit with a smaller sample size, as monotherapy.

Abbreviations
AAP: Atypical antipsychotics; ADHD: Attention-deficit/hyperactivity disorder; CI: Confidence interval; Conners 3-P: Conners 3-Parents; CRF: Case report form; GXR: Guanfacine extended-release; MedDRA: Medical Dictionary for Regulatory Activities; NICHQ: National Institute for Children’s Health Quality; SD: Standard deviation; SNAP-V/26: Swanson, Nolan, and Pelham-IV; TEAE: Treatment-emergent adverse event; WFRS-P: Weiss Functional Impairment Rating Scale-Parent Report.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13034-021-00402-5.

Acknowledgements
The authors would like to thank the following practitioners and clinics for their participation in this study: Laurence Jerome, London, ON; Anne Richards, Toronto, ON; Joseph Sadek, Atlantic ADHD Center, Dartmouth, NS; Halifax Healthcare, Oakville, ON; Center for Pediatric Excellence, Ottawa, ON; Danielle Houdé, Clinique Medicale Valcartier, Courcelette, QC; Doron Almagor, Possibilities Clinic, Toronto, ON; Joan Flood, Shoniker Clinic, Scarborough, ON; Kamran Bordbar, Unicare Clinic, North York, ON; Sohail Khattak, XCeed Clinical Research Inc, Ajax, ON.

The authors acknowledge Shawna Kelly (Research Assistant, Halton Healthcare, Oakville, ON), Angela C Vanderwiel-Ferguson (Toronto, ON), and Tamara Werner-Kiechle (formerly of Shire Human Genetic Therapies, Inc., a Takeda company) and William Spalding (Shire Human Genetic Therapies, Inc., a Takeda company) for their contributions to the study.

Under the direction of the authors, Lindsay Craik, formerly of Caudex, New York, provided writing assistance for this publication, funded by Shire Human Genetic Therapies, Inc., a Takeda company. Editorial assistance in formatting, proofreading, copyediting, fact checking, and coordination and collation of comments was also provided by Caudex, funded by Shire Human Genetic Therapies, Inc., a Takeda company, and by Takeda Canada Inc.

The affiliations for Christopher J. Reaume and Kenneth Handelman were those at the time the study was undertaken.

Prior presentations
Data from this manuscript were presented as an e-poster at the International Congress on ADHD, March 19–21, 2018, and as posters at 5th Colloque International de Langue Française sur le TDAH, June 28–29, 2018, 38th Annual Canadian Academy of Child and Adolescent Psychiatry Conference, September 16–18, 2018, 5th EUNETHYDIS International Conference, September 23–26, 2018, and 7th World Congress on ADHD, April 25–28, 2019.

Authors’ contributions
All authors made substantial contributions to the conception and design of the study, or acquisition of data, or analysis and interpretation of data, drafted the article or revised it critically for important intellectual content. All authors read and approved the final manuscript.

Funding
This study was funded by Takeda Canada, Inc. Data analysis was performed by JSS Medical Research Inc. Shire Human Genetic Therapies, Inc., a Takeda company, provided funding to Caudex, Oxford, UK, for support in writing and editing this manuscript. Takeda Canada Inc. provided support for editorial assistance in formatting, proofreading, copyediting, and coordination and collation of comments. Although employees of Shire Human Genetic Therapies, Inc., a Takeda company, were involved in the design, collection, analysis, interpretation, and fact checking of information, the content of this manuscript, the interpretation of the data, and the decision to submit the manuscript for publication in Child and Adolescent Psychiatry and Mental Health was made by the authors independently.

Availability of data and materials
The data that support the findings of this study are available from JSS Medical Research Inc., but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of Takeda Canada Inc.
Declarations

Ethics approval and consent to participate
Prior to any study activity, the proposed protocol and CRFs were reviewed and approved by a central ethics committee (Institutional Review Board Services, now part of Advarra), and local ethics review boards (Halton Healthcare Research Ethics Committee, Nova Scotia Health Authority Research Ethics Board [File number 1021786]) as required for individual sites. Where applicable, patient consent for review of their charts was sought.

Consent for publication
Not applicable.

Competing interests
JVŠ has received compensation for serving as a consultant and speaker for Janssen, Purdue Pharma, and Takeda Canada Inc. JVŠ has also received educational grants from Janssen, Purdue Pharma, and Takeda Canada Inc., and research grants from Emalex, Janssen, Nuvelution, Purdue Pharma, Takeda Canada Inc., Biohaven and Teva. JVŠ has also participated in advisory boards and speaker bureaus for Janssen, Purdue Pharma, and Takeda Canada Inc. JVŠ owns stocks in Johnson & Johnson. SKG is an employee of Takeda Canada Inc. SKG owns stock/stock options in Takeda. CJR was an employee of Shire Pharma Canada ULC (now Takeda Canada Inc.) at the time of the study. CJR is currently an employee of Medison Canada. KH has received research grants and speaking honoraria from Takeda Canada Inc., and has acted on advisory boards and speaker bureaus for Sunovion, Janssen, Purdue, and Takeda Canada Inc.

Author details
1 Canada ULC, A Takeda Company (Now Takeda Canada Inc.), Toronto, ON, Canada. 2 Takeda Canada Inc., Toronto, ON, Canada. 3 Shire Pharma Canada ULC, A Takeda Company (Nov Takeda Canada Inc.), Toronto, ON, Canada. 4 Halton Healthcare, Oakville, ON, Canada.

Received: 17 April 2021 Accepted: 3 September 2021
Published online: 04 October 2021

References
1. Wehmeier PM, Schacht A, Barkley RA. Social and emotional impairment in children and adolescents with ADHD and the impact on quality of life. J Adolesc Health. 2010;46(3):209–17.
2. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and meta-regression analysis. Am J Psychiatry. 2007;164(6):942–8.
3. Visser SN, Danielson ML, Bitsko RH, Holbrook JR, Kogan MD, Ghandour RM, et al. Trends in the parent-report of health care provider-diagnosed and medicated attention-deficit/hyperactivity disorder: United States, 2003–2011. J Am Acad Child Adolesc Psychiatry. 2014;53(1):34-46.e32.
4. Haukå TS, Lau C, Wing LE, Kundvik P, Tu K. ADHD treatment in primary care: demographic factors, medication trends, and treatment predictors. Can J Psychiatry. 2017;62(6):393–402.
5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5). 5th ed. Arlington: American Psychiatric Publishing; 2013.
6. NICE. Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults. London: British Psychological Society; 2009.
7. Pelham WE, Foster EM, Robb JA. The economic impact of attention-deficit/hyperactivity disorder in children and adolescents. J Pediatr Psychol. 2007;32(6):711–27.
8. Birmbaum HG, Kessler RC, Lowie SW, Scinicri K, Greenberg PE, Leong SA, et al. Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000. Curr Med Res Opin. 2005;21(2):195–206.
9. Centre for ADHD Awareness Canada. Paying attention to the cost of ADHD. 2013. http://caddac.ca/adhd/wp-content/uploads/2017/01/Socio-economic-Policy-Paper-1.pdf. Accessed 17 Dec 2020.
10. American Academy of Pediatrics. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011;128(5):1007–22.
11. Elbe D, Reddy D. Focus on guanfacine extended-release: a review of its use in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry. 2014;23(1):48–60.
12. The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56(12):1073–86.
13. Olsson M. New options in the pharmacological management of attention-deficit/hyperactivity disorder. Am J Manag Care. 2004;10(suppl 4):S117–24.
14. Canadian ADHD Resource Alliance (CADDRA). Canadian ADHD practice guidelines. 4th ed. Toronto: CADDRA; 2018.
15. Takeda Canada Inc. Intuniv XR product monograph. 2020. https://pdf.hrees.ca/dpt_pm/00059142.PDF. Accessed 17 Sept 2021.
16. Kabul S, Alatome C, Montejano LB, Farr AM, Clemović DB. Real-world dosing patterns of atomoxetine in adults with attention-deficit/hyperactivity disorder. CNS Neurosci Ther. 2015;21(2):936–42.
17. Greven P, Siskina V, Chen YJ, Curtis TG, Makin C. Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany. Eur J Health Econ. 2017;18(7):893–904.
18. Biederman J, Melmed RD, Patel A, McMurtie K, Konow J, Lyne A, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics. 2008;121(1):e73-84.
19. Sallee FR, McGough J, Wigal T, Donahue J, Lyne A, Biederman J, et al. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009;48(2):155–65.
20. Spencer TJ, Greenbaum M, Ginsberg LD, Murphy WR. Safety and effectiveness of coadministration of guanfacine extended release and psycho-stimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19(5):501–10.
21. Connor DF, Firding RL, Collins SH, Sallee F, Lopez FA, Lyne A, et al. Effects of guanfacine extended release on oppositional symptoms in children aged 6–12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. CNS Drugs. 2010;24(9):755–68.
22. Collins SH, Lopez FA, Vince BD, Tumbow JM, Farrand K, Lyne A, et al. Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2011;21(2):111–20.
23. Wilens TE, Bukstein O, Brams M, Cutler AJ, Childress A, Rugino T, et al. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2012;51(1):74–85.
24. Newcorn JH, Stein MA, Childress AC, Youcha S, White C, Enright G, et al. Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration. J Am Acad Child Adolesc Psychiatry. 2013;52(9):921–30.
25. van Stralen JPM. A controlled trial of extended-release guanfacine and psychostimulants on executive function and ADHD. J Atten Disord. 2020;24(2):318–25.
26. Bello NT. Clinical utility of guanfacine extended release in the treatment of ADHD in children and adolescents. Patient Prefer Adherence. 2015;9:877–85.
27. Swanson JM. The SNAP IV teacher and parent rating scale. 2011. https://medicine.usask.ca/documents/psychiatry/snap-iv-form.pdf. Accessed 3 Dec 2019.
28. National Institute for Children’s Health Quality. NICHQ Vanderbilt Assessment Scales: Used for diagnosing ADHD. 2002. https://www.nichq.org/sites/default/files/resource-file/NICHQ_Vanderbilt_Assessment_Scales.pdf. Accessed 17 Dec 2020.
29. Conners CK. Conners 3-Parent Assessment Report. 2008. https://www.pearsonclinical.com.au/files/7443014712288127.pdf. Accessed 17 Dec 2020.
30. Weiss MD. Functional Impairment Rating Scale—Parent Report (WFIRS-P). 2014. https://caddra.ca/pdfs/caddraGuidelines2011WFIRS_P.pdf. Accessed 17 Dec 2020.

31. Cutler AJ, Brans M, Bukstein O, Mattingly G, McBurnett K, White C, et al. Response/remission with guanfacine extended-release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2014;53(10):1092–101.

32. Ramos BP, Stark D, Verduzco L, van Dyck CH, Arnsten AFT. Alpha2A-adrenoceptor stimulation improves prefrontal cortical regulation of behavior through inhibition of cAMP signaling in aging animals. Learn Mem. 2006;13(6):770–6.

33. Arnsten AF, Scalf L, Findling RL. Alpha2-adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: emerging concepts from new data. J Child Adolesc Psychopharmacol. 2007;17(4):393–406.

34. Yi F, Liu S-S, Luo F, Zhang X-H, Li B-M. Signaling mechanism underlying α2A-adrenergic suppression of excitatory synaptic transmission in the medial prefrontal cortex of rats. Eur J Neurosci. 2013;38(3):2364–73.

35. Beau-Lejdstrom R, Douglas I, Evans SJW, Smeeth L. Latest trends in ADHD drug prescribing patterns in children in the UK: prevalence, incidence and persistence. BMJ Open. 2016;6(6):e010508.

36. Park-Wyllie L, Van Stralen J, Almagor D, Dobson-Belaire W, Charland K, Smith A, et al. Medication persistence, duration of treatment, and treatment-switching patterns among Canadian patients taking once-daily extended-release methylphenidate medications for attention-deficit/hyperactivity disorder: a population-based retrospective cohort study. Clin Ther. 2016;38(8):1789–802.

37. Wang L-J, Yang K-C, Lee S-Y, Yang C-J, Huang T-S, Lee T-L, et al. Initiation and persistence of pharmacotherapy for youths with attention deficit hyperactivity disorder in Taiwan. PLoS ONE. 2016;11(8):e0161061.

38. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(suppl 1):1–93.

39. Pringsheim T, Panagiotopoulos C, Davidson J, Ho J, et al. Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth. J Can Acad Child Adolesc Psychiatry. 2011;20(3):218–33.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.